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Fiona B Carr, Sandrine M Géranton and Stephen P Hunt*Abstract
Background: Descending control of nociceptive processing, by pathways originating in the rostral ventromedial
medulla (RVM) and terminating in the dorsal horn, contributes to behavioural hypersensitivity in a number of pain
models. Two facilitatory pathways have been identified and are characterized by serotonin (5-HT) content or
expression of the mu opiate receptor. Here we investigated the contribution of these pathways to inflammatory
joint pain behaviour and gene expression changes in the dorsal horn.
Results: Selective lesion of the descending serotonergic (5-HT) pathway by prior intrathecal administration of
5,7-dihydroxytryptamine attenuated hypersensitivity at early time points following ankle injection of CFA. In a separate
study ablation of the mu opioid receptor expressing (MOR+) cells of the RVM, by microinjection of the toxin
dermorphin-saporin, resulted in a more prolonged attenuation of hypersensitivity post CFA. Microarray analysis was
carried out to identify changes in dorsal horn gene expression associated with descending facilitation by the MOR+
pathway at 7d post joint inflammation. This analysis led to the identification of a number of genes including the
chemokines Cxcl9 and Cxcl10, their common receptor Cxcr3, and the proinflammatory gene Nos2 (inducible nitric oxide
synthase, iNOS).
Conclusions: These findings demonstrate that joint pain behaviour is dependent in part on descending facilitation via
the RVM, and identify a novel pathway driving CXC chemokine and iNOS expression in the dorsal horn.
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Joint pain is a significant clinical problem [1-3]. In con-
ditions such as osteoarthritis and rheumatoid arthritis
the extent of peripheral joint pathology does not always
correlate with pain levels [4,5] suggesting chronic joint
pain may be due in part to changes within the central
nervous system. A number of studies have investigated
the role of peripheral sensitisation in joint pain in animal
models [6-12]. However central sensitisation of the dor-
sal horn has also been reported to contribute to mech-
anical hypersensitivity [8,13-15]. Recently a role for
dorsal horn immune cells in joint pain has also been de-
scribed [16,17].* Correspondence: hunt@ucl.ac.uk
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unless otherwise stated.Descending facilitation via the rostral ventromedial me-
dulla (RVM) has been shown to be an important factor in a
number of animal models of chronic pain [18]. Two largely
independent descending facilitatory pathways have been de-
scribed. One originates from 5-HT (serotonin) positive cell
bodies within the RVM and has been shown to release 5-
HT into the dorsal horn, and the other is characterized by
expression of the mu opioid receptor (MOR+) on cell
bodies within the RVM [19]. MOR+ cells are believed
to correspond to the electrophysiologically defined,
pro-nociceptive ON cell population [19,20]. Depletion of
MOR+RVM neurons by administration of the selective
neurotoxin dermorphin-saporin has been shown to prevent
the maintenance of neuropathic pain behaviour [21-23].
Similarly, manipulation of the descending 5-HT pathway
has been shown to attenuate pain in animal models. Thus
reducing 5-HT synthesis within the RVM [24], or depletion
of 5-HT containing descending fibres within the spinal cord. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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following both neuropathic injury and cutaneous
inflammation.
To date, the role of descending facilitation in joint
pain behaviour has not been investigated but it is likely
that the MOR+ and 5-HT pathways also contribute to
behavioural hypersensitivity in models of joint pain. In
addition, little is known regarding the molecular mecha-
nisms within the dorsal horn that are modulated by de-
scending facilitation. The aim of the present study was
to investigate the contribution of descending facilitation
to behavioural hypersensitivity in a model of ankle joint
inflammation, using selective lesion of the MOR+ or 5-
HT pathways. To better understand the molecular
mechanisms in the dorsal horn underlying descending
facilitation, microarray analysis was also carried out to
identify dorsal horn genes regulated by the MOR+ de-
scending pathway.
Results
Lesion of descending 5-HT fibres attenuates mechanical
hypersensitivity at 1d and 2d post CFA
To determine the contribution of the descending 5-HT
to mechanical hypersensitivity following ankle joint in-
flammation, animals were divided into two groups, re-
ceiving intrathecal injection of 5,7-DHT or saline. These
were subdivided into groups which underwent CFA in-
jection or sham procedure. Paw withdrawal thresholds
were measured prior to 5,7-DHT or saline treatment,
and monitored up to 7d post CFA injection. Three-way
analysis of variance (ANOVA) with repeated measures
was carried out, with time as the within-subject factor
and intrathecal injection (5,7-DHT or saline) and CFA
injection (CFA or sham) as the between-subjects factors
(n = 6–7). All animals that received CFA injection devel-
oped mechanical hypersensitivity of the ipsilateral hind-
paw from 2 h post injection (p < 0.001, F (1, 22) = 87.3).
Examining the time window from 6 h to 3d indicated a
significant interaction of intrathecal injection x CFA
(p = 0.031, F (1, 22) = 5.3), and subsequent LSD post hoc
tests indicated a significant effect of 5,7-DHT treatment
on CFA behaviour at 1d and 2d after injection (p = 0.01
and p = 0.037) (Figure 1A).
Paw withdrawal thresholds of the contralateral hind-
paw were also measured. No main effect of CFA injec-
tion was identified, indicating contralateral mechanical
threshold is unaffected by CFA injection (Figure 1B).
To confirm ablation of 5-HT fibres from the dorsal
horn, 5-HT immunohistochemistry was carried out on a
subset of animals at the end of behavioural experiments.
The lumbar L4-L6 region of the spinal cord from a total
of 8 rats (2 from each treatment group, in each of the
two experimental batches) were sectioned and stained
for 5-HT. In all 5,7-DHT treated animals it was foundthat as expected, 5-HT positive punctae were almost
completely absent within the dorsal horn, compared
with saline injected controls in which extensive 5-HT la-
belling was observed. Representative images of 5,7-DHT
treated and saline control animals are shown in Figure 2.
Lesion of descending MOR+ cell pathway attenuates
mechanical hypersensitivity from 1-7d post CFA
To determine the contribution of the descending MOR+
pathway to mechanical hypersensitivity following ankle
joint inflammation, animals were divided into two groups,
receiving intra-RVM injection of dermorphin-saporin
(1.5pmole) or saline. The dose used was modified from the
3pmole described by others previously [21-23], and similar
to a recent study that used a dose of 1.8pmole dermorphin-
saporin in a study of stress induced hyperalgesia [27] as
3pmole doses of dermorphin-saporin were found to pro-
duce non-specific damage to brainstem neurons. Pilot ex-
periments were carried out to assess the efficacy of
dermorphin-saporin in specifically ablating MOR+ cells
28 days after injection into RVM The RVM region (n = 3
dermorphin-saporin treated group, and n = 3 from saline
injected controls) were sectioned and stained for MOR.
Counting of MOR+ cells was carried out manually
using an immunofluorescence microscope. As expected,
dermorphin-saporin microinjection led to a significant
decresase in MOR+ cell number compared to saline
injected controls. A decrease in MOR+ cell numbers in the
1.5pmole group (155 ± 4) was found when compared with
saline control (208.7 ± 14.2) (independent samples t-test,
p = 0.022, Figure 3B). Representative immunohistochemis-
try from dermorphin-saporin and sham treated animals are
shown in Figure 3A. To confirm that the cell depletion was
specific to MOR+ neurons, NeuN double labelling was car-
ried out in a separate set of sections. High power single
plane confocal images (Figure 3C), indicate the presence of
surviving NeuN+, MOR- cells in dermorphin-saporin
treated animals. This confirms specificity of the depletion
for MOR expressing neurons.
RVM lesioned rats were further subdivided into
groups that underwent CFA injection or sham proced-
ure. Paw withdrawal thresholds were measured prior to
dermorphin-saporin or saline treatment, and monitored
up to 7d post CFA injection. Three-way ANOVA with
repeated measures was used to analyse the ipsilateral
paw withdrawal thresholds. All CFA treated animals
showed an increase in mechanical hypersensitivity on
the ipsilateral hindpaw (p < 0.001, F(1,25) = 228.1). A
subsequent two-way ANOVA with repeated measures
was carried out on the two CFA treated groups, from 1d
to 7d post CFA, and it was found that there was an
overall main effect of dermorphin-saporin treatment on
paw withdrawal thresholds from 1d to 7d post CFA in-
jection (p = 0.015, F (1, 25) = 6.8). LSD post hoc analysis
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Figure 1 Attenuation of mechanical hypersensitivity by 5,7-DHT treatment. A). Attenuation of mechanical hypersensitivity in 5,7-
dihydroxytryptamine treated rats following ankle joint inflammation. Ipsilateral paw withdrawal thresholds were significantly higher in 5,7-DHT
treated animals compared with saline controls, at 1d and 2d following CFA injection. Pre-IT indicates the baseline prior to intrathecal injection,
post-IT indicates baseline after IT injection. B). Paw withdrawal thresholds of the contralateral hindpaw were not altered by CFA injection or by
5,7-DHT pre-treatment. Data is presented as log2 (paw withdrawal threshold in g) and mean ± SEM. Line indicates significant 5,7-DHT x CFA
interaction in ANOVA, * indicates p < 0.05, LSD post hoc tests. n = 6–7 per group.
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and 6d (Figure 4A).
Paw withdrawal thresholds of the contralateral hind-
paw were also measured. No main effect of CFA injec-
tion was identified, indicating contralateral mechanical
sensitivity was unaffected by CFA injection (Figure 4B).At the end of the behavioural experiment, animals were
culled and the dorsal quadrants of the lumbar spinal cord
were dissected for microarray experiments. The brains of
these animals were also removed, sectioned and stained
using DAPI to identify the needle tracts. The approximate
anterior-posterior, dorsal-ventral and lateral coordinates for
Saline 5,7 DHT
Figure 2 Immunohistochemistry confirms depletion of 5-HT fibres by 5,7-DHT treatment. Representative images indicate that 5,7-DHT
treatment leads to a complete loss of 5-HT punctate immunoreactivity within the dorsal horn. Top row x 5 magnification, scale bar indicates
400 μm, bottom row x 10 magnification, scale bar indicates 200 μm. Tissue was taken at 7d post CFA injection (13d following 5,7-DHT depletion).
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this experiment and the approximate locations in the CFA
groups are shown (Figure 5). For all other animals it was
found that at least one of the bilateral injections was within
or close to the dorsal-ventral boundary of the RVM. Simi-
larly the anterior-posterior coordinates were satisfactory for
all animals (within −10.5 mm to −11.8 mm from Bregma).
Characterisation of dorsal horn genes regulated by the
MOR+ cell pathway at 7d post CFA
Gene expression profiles of the dorsal horn of rats le-
sioned with dermorphin-saporin were compared to sa-
line injected control animals, at 7d following ankle
injection of CFA. Following Limma testing, the non-
adjusted p-value was used for ranking purposes, as de-
scribed previously [28]. Only those genes with a non-
adjusted p value of < 0.05 were considered as differen-
tially regulated (2616 transcripts in total). Genes without
an official gene symbol were also removed (leaving 1668
transcripts in total). The remaining transcripts were then
ranked by fold change. An arbitary fold change cut-off of
1.2 was set, and this resulted in a final list of 129 genes.
Additional file 1: Table S1 lists all of these genes with
their ranking on the list based on fold change. The ma-
jority of the genes (76%) were downregulated in the
dermorphin-saporin group.
To identify biological functions over represented
within this list, DAVID bioinformatics software was
used. This is a freely available online tool (http://david.
abcc.ncifcrf.gov) and it was used to perform functionalannotation of the genes in the list based on the gene
ontology (GO) database. This consists of annotations of
gene function using defined GO terms in three areas:
biological process, cellular compartment and molecular
function [29]. This analysis produced a list of 35 GO
terms significantly enriched within the list. Functional
annotation clustering was then carried out, to consoli-
date groups of similar annotations to minimise redun-
dancy in function [30]. This analysis resulted in the
identification of 20 clusters of annotations enriched
within the gene list (Figure 6A). Full lists of genes within
each cluster are shown in Additional file 2: Table S2.
The most significantly enriched cluster (with the high-
est EASE score, see methods) corresponded to genes
with ribosomal function. The annotations of this cat-
egory refer to ribosomal structural proteins, as well as
genes involved in translation and those with a cytosolic
location. This included several large ribosomal subunit
components (e.g. Rpl32 and Rpl21). Also within this
group was Ccnb2, which encodes the cell-cycle mediator
cyclin B2. This was one of the highest ranking fold
changes identified with a 1.85 increase in the
dermorphin-saporin group.
A second significant cluster contains genes with anno-
tations for defense response, which includes a number of
genes involved in immune system function. Among
these was Nos2, which encodes the enzyme nitric oxide
synthase 2 (inducible nitric oxide synthase), which is im-
plicated in inflammatory responses [31]. The next cluster
contains genes associated with chemotaxis, which are
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Figure 3 Immunohistochemistry confirms depletion of MOR+ neurons by dermorphin-saporin microinjection to the RVM. A).
Representative images illustrate MOR+ expression in dermorphin-saporin and saline control animals (approximately −10.5 mm from Bregma).
Depletion of MOR+ cells can be observed in the bilaterally injected dermorphin-saporin (DS, 3pmole/96 ng) animal. Scale bar indicates 200 μm.
Nucleus raphe magnus (NRM) and nucleus reticularis gigantocellularis (GiA), components of the RVM are shown. B). Cell counts indicate a
significant decrease in MOR+ cell number in animals treated with 1.5pmole dermorphin-saporin (DS). Cell counts were calculated as the sum of
the top five sections per animal, and data shown here as mean ± SEM per group. n = 3 – 4, *p = 0.022, independent samples t-test.
C). Representative single plane confocal images of MOR immunohistochemistry in the 1.5pmole dermorphin-saporin group and saline control.
Double labelling with NeuN indicated that although many MOR+ neurons are depleted at this dose, some surviving MOR- neurons remain in the
region, indicated by white arrows. Scale bars indicate 25 μm.
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http://www.molecularpain.com/content/10/1/39also involved in immune system function and inflamma-
tory responses. This cluster included the chemokines
Cxcl9 and Cxcl10. All of these immune system and
chemotaxis related genes were downregulated in the
dermorphin-saporin group, suggesting that immune cell
activation in the dorsal horn may be reduced in the
dermorphin-saporin group. Interestingly, the GPCR sig-
nalling cluster contained the chemokine receptor Cxcr3
which binds the chemotaxis ligands Cxcl9 and Cxcl10.Validation of selected ribosomal and immune system
related genes by RT-qPCR
A number of genes identified by the microarray analysis
were selected for validation by RT-qPCR. These were se-
lected from the four most significantly enriched func-
tional annotation clusters: ribosomal function, defence
response, chemotaxis and GPCR signalling. For each se-
lected gene, 4 – 6 samples per group (dermorphin-
saporin + CFA v saline + CFA) were used for validation.
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Figure 4 Attenuation of mechanical hypersensitivity by dermorphin-saporin microinjection. A). Attenuation of mechanical hypersensitivity
of the ipsilateral hindpaw in dermorphin-saporin (DS, 1.5pmole in total, 0.75pmole each side) pretreated rats following ankle joint inflammation.
Paw withdrawal thresholds were significantly higher in the dermorphin-saporin group than in saline injected controls from 1 to 7d post CFA
injection. Line indicates overall effect of DS treatment from 1d to 7d post CFA in ANOVA with repeated measures. *p < 0.05 and **p < 0.01 with
LSD post hoc tests. There was no effect of pre-treatment on baseline paw withdrawal thresholds. B). Paw withdrawal thresholds of the
contralateral hindpaw were not altered by CFA injection or by dermorphin-saporin pre-treatment, p > 0.05, three-way ANOVA with repeated
measures. Data is presented as log2 (paw withdrawal threshold in g) and mean ± SEM, n = 8 in CFA groups, n = 6 /7 in sham groups.
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gene, β-actin.
The most statistically significant cluster (with the high-
est enrichment score) contained genes with ribosomal
functions which may be of interest as translation is im-
portant in many forms of neuronal plasticity, including
pain states. As an example of a gene from this cluster,downregulation of the ribosomal protein Rpl32, which
had a fold decrease of 1.68 on the microarray, was con-
firmed by RT-qPCR (p = 0.0399, Figure 6B). Ccnb2, en-
coding the protein Cyclin B2, was one of the highest
fold gene changes identified by the array, with a 1.85
fold increase in the dermorphin-saporin treated animals
and ranking number 4 on the list. It was also among the
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Figure 5 Confirmation of bilateral microinjection sites of animals used in microarray experiment. Only animals from the dermorphin-saporin +
CFA group (dots labelled DS) and saline + CFA group (dots labelled saline) are shown. The numbers indicate the approximate anterior-posterior distance
from Bregma in mm.
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http://www.molecularpain.com/content/10/1/39minority of genes that were upregulated in the
dermorphin-saporin group. This increase was confirmed
by RT-qPCR, with a significant increase in expression
found in the dermorphin-saporin + CFA treated group
compared with saline + CFA controls (p = 0.0041,
Figure 6B).
The next most significant clusters, defence response and
cheomotaxis, contained a number of immune system re-
lated genes. Nos2, encoding the enzyme nitric oxide syn-
thase 2 (inducible nitric oxide synthase, iNOS) has been
shown to play a role in central sensitisation in both inflam-
matory and neuropathic pain states [32-35]. Nos2 was
found to be downregulated in the dermorphin-saporin
group. RT-qPCR confirmed a significant decrease in Nos2
expression in the dermorphin-saporin group (p = 0.022,
Figure 6B).
Cxcl10 was among the genes in the chemotaxis clus-
ter. This is a member of the CXC family of chemokines
which are induced by IFN-y. CXCL10 is a ligand for the
G-protein coupled chemokine receptor Cxcr3 [36] which
was also identified on the microarray. Cxcl10 and Cxcr3
were downregulated in the dermorphin-saporin group in
the microarray analysis, and RT-qPCR confirmed a sig-
nificant decrease in all both genes (Cxcl10 p = 0.0132,
Cxcr3 p = 0.0379, Figure 6B) Although these genes have
been reported to be upregulated in the DRG in certain
inflammatory conditions [37,38], the present study is thefirst to identify regulation this chemokine family within
the dorsal horn.
Discussion
Few studies to date have addressed the role of the de-
scending system in joint pain, except for a number of
electrophysiological studies of descending inhibition, and
only in the acute phase of the pain state [39-41]. Here
we have combined lesion of the RVM with behavioural
studies to address the role of descending facilitation in a
model of inflammatory joint pain. In addition microarray
analysis has led to the identification of a number of pos-
sible mediators of descending facilitation at the level of
the dorsal horn.
We first investigated the role of the descending 5-HT
pathway in the development of mechanical hypersensi-
tivity following ankle injection of CFA. Previous studies
have indicated the descending 5-HT pathway contributes
to the maintenance of behavioural hypersensitivity in
neuropathic pain [26]. In the present study intrathecal
administration of the selective toxin 5,7-DHT attenuated
mechanical hypersensitivity at 1d and 2d post CFA injec-
tion, suggesting that the 5-HT pathway contributes in a
time-dependent manner to hypersensitivity in this pain
state. In the hours following inflammation and at later
time points, the 5-HT system does not appear to facili-
tate the pain state. This supports previous findings by
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Figure 6 DAVID bioinformatics and RT-qPCR validation. A). 20 functional annotation clusters were identified using the DAVID online
bioinformatics tool. The horizontal bars indicate the number of genes that are upregulated (to the right) or downregulated (to the left) in each
cluster. Joined bars indicate the upregulated and downregulated genes for each cluster. For clarity, alternate black and white bars are used
between clusters. For details of the genes contained in each cluster see Additional file 2: Table S2. B). A number of genes were selected for
validation by RT-qPCR. 2ΔCt values were obtained for each group, using actin as the housekeeping gene. Data is presented as fold change of the
dermorphin-saporin (DS) + CFA group over the saline + CFA control group, mean ± SEM. n = 4 – 6 per group, *p < 0.05 independent
samples t-test.
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(TPH) enzyme within the RVM attenuates mechanical
hypersensitivity at 1d – 3d following plantar injection of
CFA [24].
Our second lesion experiment targeted the electro-
physiologically defined ON cells of the RVM, which are
believed to be facilitatory in nature [42]. Although ON
cells do not have a single neurochemical classification,
they can be identified by their direct responsiveness to
morphine implying that they express the mu opioid re-
ceptor (MOR) [19,20]. This characteristic has been
exploited previously by others to ablate the MOR ex-
pressing (MOR+) neurons of the RVM using the select-
ive neurotoxin dermorphin-saporin [21-23]. We foundthat, as with 5,7-DHT treatment, MOR+ cell depletion
attenuated mechanical hypersensitivity. However this ef-
fect was more prolonged than for 5,7-DHT depletion,
with significant attenuation observed from 1d to 7d post
CFA injection. This increased attenuation may have been
because some MOR positive neurons are also 5-HT
positive [20] and lesions of RVM therefore would have
caused partial ablation of both descending control
pathways.
However while both the 5-HT and MOR+ cell path-
ways played a role in regulating the mechanical hyper-
sensitivity associated with joint inflammation, the
magnitude of attenuation in both lesion studies was con-
siderably smaller than that observed in neuropathic pain
Carr et al. Molecular Pain 2014, 10:39 Page 9 of 14
http://www.molecularpain.com/content/10/1/39states [21-23]. Similarly the time of onset of descending
facilitation differs in the present study than that shown
previously for neuropathic pain. The previous dermorphin-
saporin studies of neuropathic pain indicated that descend-
ing facilitation is required for the maintenance but not the
induction of behavioural hypersensitivity [21-23]. In con-
trast, descending facilitation of joint pain is evident from
one day onwards. This suggests that in neuropathic injury,
descending facilitation is required for the maintenance of
the pain state, whereas in joint inflammation descending fa-
cilitation contributes to both the induction and mainten-
ance phases. It should be noted that we have measured
mechanical hypersensitivity of the hindpaw, which is a re-
flection of secondary hyperalgesia. We did not address pri-
mary hyperalgesia of the inflamed joint, which would
require measurement of load bearing and other more direct
measures of primary sensitization. Nonetheless, the present
findings support previous studies which suggested that de-
scending facilitation modulates secondary hyperalgesia
[43-45].
While the contribution of descending facilitation to
central sensitisation and behavioural hypersensitivity in a
variety of pain states has been extensively studied
[21,22,24,25] little is known about the molecular mecha-
nisms underlying descending facilitation. Microarray
analysis has however been used to characterise changes
in dorsal horn gene expression at 2 h-7d following ankle
injection of CFA [28]. To build on these findings, the
present study aimed to examine the contribution of de-
scending facilitation to the regulation of gene expression
at the 7d time point. Microarray analysis was carried out
on two groups, both with CFA inflammation, and with
dermorphin-saporin or saline pretreatment as the only
variable. In this way the analysis revealed genes that are
regulated in this pain state by the MOR+ RVM descend-
ing pathway.
A number of cellular mechanisms could potentially
contribute to descending facilitation of dorsal horn ex-
citability. Changes in receptor availability, presynaptic
release of neurotransmitters, post-synaptic changes in
intracellular signalling pathways, transcriptional regula-
tion and immune cell activation are all key features of
central sensitisation [46] and could be subject to modu-
lation by descending facilitation. However, surprisingly
few genes with neuronal annotations were identified in
our analysis, while many genes associated with immune
cell function were identified.
A prominent role for immune cells in dorsal horn in me-
diating central sensitisation and behavioural hypersensitivity
has been established [16,17,47,48] and immune system re-
lated genes are a feature of many other microarray studies
of the dorsal horn [47-49]. Many of the immune related
genes identified by our microarray analysis were found
to be downregulated by dermorphin-saporin treatment,suggesting that descending facilitation by the MOR+ cell
pathway is a positive modulator of immune cell processes
within the dorsal horn.
Among the genes confirmed by RT-qPCR was Nos2,
which encodes the enzyme inducible nitric oxide syn-
thase (iNOS). Nos2 gene expression is induced in per-
ipheral immune cells during inflammation, and has also
been shown to be regulated in microglia and astrocytes
[50]. Nitric oxide (NO) itself has been implicated in cen-
tral sensitisation in various pain states [32,51-55]. Al-
though the focus has largely been on neuronal NOS as
the enzyme responsible for spinal production of NO, a
number of reports have implicated iNOS protein in in-
flammatory and neuropathic pain states [32-35]. Bilateral
induction of Nos2 in the dorsal horn has been shown to
occur following ankle injection of CFA [33] and our
present data suggests that Nos2 expression may be mod-
ulated, at least in part, by descending pathways. Interest-
ingly upregulation of Nos2 occurs in the spinal cord in a
model of stress-induced hyperalgesia, and CCK signal-
ling within the RVM is required for this process [56].
Our finding also suggests that Nos2 gene expression in
the dorsal horn is modulated by descending pathways.
One of the key findings of our present study was the
downregulation of two members of the same family of
chemokines in the dermorphin-saporin treated group.
The expression of these genes was not altered by CFA
joint inflammation alone [28]. Chemokines are small
molecular weight proteins which regulate leukocyte mi-
gration and activation and act as a key component of the
immune response [57]. Within the dorsal horn, a num-
ber of chemokines have been shown to play a role in
various pain models and there is an established role for
chemokines such as CX3CL1 (fractalkine) and CCL2
within the dorsal horn in both neuropathic and inflam-
matory pain states [16]. Cxcl9 and Cxcl10 are members
of the interferon gamma (IFN-γ) inducible subset of
CXC chemokines. A number of previous studies have
suggested a role for the cytokine IFN-y within the dorsal
horn in chronic pain states [58-61]. As targets of IFN-y
signalling, Cxcl9 and Cxcl10 may therefore be involved
in nociception in the dorsal horn. Notably the shared re-
ceptor for these chemokines, Cxcr3, was also downregu-
lated in the dermorphin-saporin treated group. The
simultaneous downregulation of these Cxcl9, Cxcl10 and
Cxcr3 suggests that this chemokine-receptor signalling
pathway may contribute to descending facilitation via
the MOR+ cell pathway, indicating a novel role for this
chemokine family in pain signalling within the dorsal
horn.
Although most studies of CXCL10 in the CNS have
focused on its expression in immune cells and role in
neuroinflammation [36] one study has demonstrated
that CXCL10 is expressed constitutively in neurons in
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Furthermore exposure of hippocampal neurons in vitro
to exogenous CXCL10 causes increased excitability [63].
Although to date, chemokines within the CNS have been
investigated predominantly as modulators of immune
cells, in future it may be of interest to investigate their
roles in neuronal transmission [64].
The expression of CXCL9 and CXCL10 is also in-
creased in the joints of patients with rheumatoid arth-
ritis [65,66] suggesting that these chemokines may
contribute to the joint pathology associated with the dis-
ease. Indeed CXCR3 receptor antagonists have also been
shown to be effective in decreasing the pathogenesis of
rheumatoid arthritis in an animal model [67]. A pronoci-
ceptive role for CXCL9, CXCL10 and CXCR3 signalling
within the dorsal horn would provide further support
for the use of chemokine antagonists in the systemic
treatment of joint pain states.
In conclusion, the present data demonstrates for the
first that time that descending facilitation contributes to
behavioural hypersensitivity following joint inflamma-
tion. This implies that in addition to targeting the under-
lying joint pathology, patients suffering from joint pain
symptoms may benefit from treatments that reduce cen-
tral sensitisation and descending facilitation. In particu-
lar, the CXC family of chemokines are subject to
regulation in the dorsal horn by descending facilitation
and therefore may be promising targets for further
studies.
Methods
Animals and inflammatory joint pain model
All studies used male Sprague–Dawley rats supplied by
the Biological Services Unit at University College
London. All procedures complied with the United King-
dom Animals (Scientific Procedures) Act 1986. Rats
were housed in cages in groups of 1 – 4 animals with a
12 h light–dark cycle (lights on at 8.00 am). Access to
food and water was ad libitum. Joint inflammation was
carried out by injection of 10 μl Complete Freund’s adju-
vant (CFA, Sigma) as described previously [28]. Sham
animals were exposed to the same anaesthesia as the
CFA treated group but received no injection.
Intrathecal administration of 5,7-DHT
Intrathecal injection of 5,7-dihydroxytryptamine was
carried out as described previously [25]. Animals (weigh-
ing 180 g – 200 g at the time of injection) were pre-
treated with 25 mg/kg i.p. desipramine hydrochloride
(Sigma) dissolved in saline to protect against noradren-
ergic toxicity one hour prior to surgery. Animals re-
ceived 10 μl of 5,7-dihydroxytryptamine (5,7-DHT)
dissolved in saline (6 μg/μl, Fluka), or saline only. Ani-
mals were allowed to recover for 6d prior to ankleinjection of CFA. The numbers per group for this behav-
ioural experiment were 5,7-DHT CFA (n = 6), saline
CFA (n = 6), 5,7-DHT sham (n = 7), saline sham (n = 7).
Microinjection of dermorphin-saporin to the RVM
Animals (weighing 200 – 250 g at the time of microinjec-
tion) were secured using a stereotaxic frame (Kopf instru-
ments), under isoflurane anaesthesia as described above. A
dental drill was used to form a single hole at the site of mi-
croinjections. Two microinjections (volume 0.5 μl each)
were carried out using a Hamilton syringe at the following
coordinates: anterior-posterior: −10.5 mm from Bregma,
lateral: ± 0.6 mm, and dorso-ventral -9 mm. Dermorphin-
saporin (Advanced Targeting Systems, 1.5pmole/μl, pre-
pared in saline) was dispensed over the course of 5 minutes.
The needle was held in place for 1 min following injection.
The skin was sutured using 5–0 Mersilk. Animals were
allowed to recover for 28 – 35d prior to ankle injection
of CFA. The numbers per group for the behavioural ex-
periment were dermorphin-saporin CFA (n = 8), saline
CFA (n = 8), dermorphin-saporin sham (n = 7), saline
sham (n = 6).
Behavioural testing
On the day of testing, animals were transported to the test-
ing room in their home cages, and placed in clear plastic
containers on a wire mesh floor. Animals were left to settle
for 15 min prior to testing. Habituation to the testing envir-
onment was achieved by taking a series of baseline mea-
sures, once daily for at least 3d prior to the initial
experimental manipulation. The mechanical paw with-
drawal threshold was obtained for the ipsilateral and
contralateral hindpaw of the animal. A series of calibrated
von Frey filaments (Stoelting) were applied to the centre of
plantar surface of the hindpaw, between the footpads. The
hairs were applied in ascending order, with 0.07 g as the
minimum and 60 g as the maximum cut off point. Each
von Frey filament was applied until bending occurred. The
filament was held in place for approximately 4 s. For each
filament the stimulus was applied five times at 5 s intervals.
The paw withdrawal threshold was defined as the lowest
weight von Frey filament at which a brisk withdrawal was
observed at least once out of the five repeated stimuli.
When a withdrawal response was observed to a given fila-
ment, no further filaments were applied. The ipsilateral
paw withdrawal thresholds for each animal were obtained
first, followed by repetition of the procedure on the contra-
lateral paw. The experimenter was blind to treatment group
of the animal in all cases.
Immunohistochemistry
For immunohistochemistry experiments, rats were
deeply anaesthetised with pentobarbital (Euthatal, 0.5 –
1 ml per animal, i.p.) and perfused transcardially with
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30 ml/min for 4 min. This was followed by 4% parafor-
maldehyde (PFA) in 0.1 M phosphate buffer (PB) for
8 min (approximately 240 ml). Brains and spinal cords
were dissected and post fixed in 4% PFA for 2 h. Tissue
was then cryoprotected in 30% sucrose (in 0.1 M PB)
and stored at 4°C until sectioning. 40 μm sections of the
lumbar spinal cord (L4 – L6) or RVM (from approxi-
mately −10.3 to −11.3 mm from Bregma) were obtained
using a freezing microtome (Leica) and stored in 5% su-
crose (in 0.1 M PB) at 4°C until staining.
Immunohistochemistry was carried out on freely float-
ing sections. Sections were blocked for one hour in 1 ml
0.1 M PB, 30 μl goat serum (Vector) and 30ul 10%
Triton X (Sigma) followed by incubation with primary
antibodies in tris-triton buffered saline (TTBS) overnight
at room temperature (5-HT, 1:75, Chemicon (MAB342);
mu opioid receptor, 1:10,000, Neuromics (RA10104)).
This was followed by the appropriate biotinylated sec-
ondary antibodies at a concentration of 1:400 for 90 min
at room temperature. Sections were then incubated
with avidin biotin complex (ABC Elite; 1:250 Vectastain
A plus 1:250 Vectastain B; Vector Laboratories,
Burlingame, CA) for 30 min. For MOR staining, this was
followed by a signal amplification step with biotinylated
tyramide solution (1:75 for 7 min; PerkinElmer,
Wellesley, MA). 5-HT immunohistochemistry did not
include the tyramide signal amplification step. Finally,
sections were incubated with FITC-avidin for 2 h (1:600,
Vector). For MOR double labelling, the sections were in-
cubated overnight at room termperature with the NeuN
primary antibody (1:1000, Cell Signalling). The sections
were incubated with the direct Alexa Fluor 594 anti-
mouse antibody (1:500, Invitrogen) for 2 h. Sections
were mounted on gelatin coated slides in 0.1 M PB,
followed by drying at room temperature and coverslip-
ping with fluoromount (Sigma).
Fluorescence labelled sections were viewed using a Leica
DMR microscope (Leica Microsystems). Images were ac-
quired using a Hamamatsu CCD digital camera (C5985,
Hammamatsu Photonics) using Openlab 4.0.4 software
(Improvision). MOR+ neurons in the RVM were counted
manually. The RVM was defined by the boundaries of
the NRM and GiA, from approximately −10.3 mm
to −11.3 mm from Bregma, according to the rat brain atlas
[68]. Counts were carried out while blind to treatment
group. All sections per animal were counted, and the the 5
sections with the highest number of MOR+ neurons, per
animal, were used for analysis. These were summed to gen-
erate a total number of positive cells per animal (n = 3 per
group), and data was plotted as the mean ± SEM per group.
For MOR/NeuN double labelling, a laser scanning
confocal microscope (Leica TCS SPE) was used. Sequen-
tial laser channel acquisition was used and all imageswere analysed as single z-planes from each channel, and
with a merged image of both channels.
Tissue collection and RNA extraction
Rats were were killed by CO₂ asphyxiation. The spinal
cord segment corresponding to the lumbar L4-L6 region
was rapidly dissected on ice, and the ipsilateral and
contralateral quadrants of the superficial dorsal horn
separated using a blade. The dorsal horn quadrants were
homogenised by hand in 700ul Qiazol (Qiagen) for 1 to
2 min. The sample was removed and passed through a
Qiashredder column and spun in the centrifuge at
14,000 rpm for 2 min. The sample was then left at room
temperature for 5 min before the RNA was extracted
using the Qiagen RNeasy kit. 140 μl chloroform was
added to the sample and the tube was capped and
shaken vigorously for 15 s. The samples were then left at
room temperature for 3 min followed by centrifugation
at 12,000 rpm at 4°C for 15 min.
The upper aqueous phase was transferred to a new tube,
with care taken to minimise cellular debris remaining in
the sample. 53% ethanol was added to the removed aque-
ous phase. This was mixed well by pipetting up and down,
and added to the RNeasy spin column, and centrifuged to
remove the ethanol. A wash step using buffer RW1 (from
the RNeasy kit) was carried out before adding DNAase I in-
cubation mix (Qiagen) to the column for 15 min. A series
of further washes using buffer RW1 and RPE from the
RNeasy kit were then performed, before a final drying step
and elution of the RNA in 25ul of RNase free H₂O. 1 μl of
each RNA sample was applied to a Nanodrop spectropho-
tometer and the concentration of RNA per sample was de-
termined in ng/μl. The contamination levels of organic
solvents (indicated by a low 260/230 value) and protein
contamination (indicated by a low 260/280 value) were also
determined using the Nanodrop. RNA was then stored at
−80°C until further use.
Microarray study
For the microarray RNA was extracted from the ipsilateral
dorsal horn from two groups of animals. One group had
dermorphin-saporin lesion of the RVM and the other saline
control injections. 28 days later both groups received a uni-
lateral intraarticular injection of CFA (as above). Tissue was
taken for for microarray analysis 7 days after CFA injection,
n =5 in both groups. RNA samples were normalised to a
concentration of 50 ng/μl in RNase free H₂O before sub-
mission to the UCL genomics service. Complementary
DNA (cDNA) synthesis was carried out using the Ambion
WT expression kit. This was followed by labelling of the
cDNA using the Affymetrix WT terminal labelling kit. La-
belled cDNA was then hybridised to Affymetrix rat gene
1.0 ST arrays and the intensity of fluorescence of the arrays
was measured using an Affymetrix gene chip scanner.
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which contain the results of the intensity calculations
per chip. Analysis of the raw data was carried out in R, a
language and environment for statistical computing and
graphics (http://www.r-project.org/), and the Bioconductor
plugin for microarray analysis was used (http://www.
bioconductor.org/). Limma testing was used to assess
differential expression between the two treatment groups.
The adjusted p values were not significant for any of the
probe sets, and for further analysis, the non-adjusted
p value was used. Previous published work by our group
has also used the non-adjusted p value [28].
The online bioinformatics tool DAVID (http://david.
abcc.ncifcrf.gov) was used to identify clusters of genes
within the list with statistically overrepresented func-
tional annotations [30].
RT-qPCR
Complementary DNA (cDNA) was synthesised from the
RNA samples. The reaction was carried by adding 0.5 μg
RNA sample to a mix of 0.2 μl Oligo dT20 (Invitrogen),
0.8 μl random nonamers (Sigma), 1 μl PCR nucleotide
mix (Promega) and bringing the reaction volume to
13 μl by adding RNase free water. This was then incu-
bated at 65°C for 5 min. The samples were then quickly
chilled on ice for 5 min. The tubes were briefly centri-
fuged to collect the mixture, and 4 μl first strand buffer
(Invitrogen), 1 μl DTT (Invitrogen), 1 μl RNaseIN ribo-
nuclease inhibitor (Invitrogen) and 1 μl of the key reac-
tion component, reverse transcriptase (Superscript III,
Invitrogen) were added. This was gently mixed by pipet-
ting up and down and the samples were then incubated
at 25°C for 5 min, 50°C for 50 min and 70°C for 15 min.
The cDNA samples were then placed quickly on ice be-
fore storage at −20°C until use in RT-qPCR assays.
Oligonucleotide primers were designed to target se-
lected genes based on the Affymetrix probe sequencesTable 1 Sequences of primers for RT-qPCR
Gene name Prim
Cyclin B2 Ccn
Ccn
Chemokine (C-X-C motif) ligand 10 Cxc
Cxc
Ribosomal protein L32 Rpl3
Rpl3
Chemokine (C-X-C motif) ligand 9 Cxc
Cxc
Chemokine (C-X-C motif) receptor 3 Cxc
Cxc
Nitric oxide synthase 2 Nos
Nos(Sigma). A list of primer sequences is given in Table 1.
RT-qPCR assays were carried out on 96 well plates, with
cDNA samples run in triplicate and controls for master
mix contamination (no cDNA added) and cDNA con-
tamination (negative control from the cDNA synthesis,
without transcriptase added) included in each plate. A
master mix solution was prepared for each plate so that
each well contained 12.5 μl SYBR green (Sigma), 9.5 μl
RNase free H₂O, and 1 μl stock solution of the forward
and reverse primers of the target gene. 1 μl cDNA was
added to the wells after they were filled with the master
solution.
The Sigma 3-step amplification protocol was used with
a Bio-Rad CFX96 PCR C100 thermal cycler. Data was
analysed using Bio-Rad CFX96 software. Ct values
(threshold cycle, which is the number of cycles taken for
the fluorescence labelling to increase above background)
were obtained for each target gene. This value is in-
versely proportional to the log of the copy number of
the cDNA in the sample. Actin was used as a house-
keeping gene. Relative gene expression was calculated
using the 2ΔCt method, where the data for each gene is
expressed in the form 2 to the power of (Ct Actin – Ct
target). N = 4–5 in both groups.
Statistical analysis
All data was analysed using SPSS (PASW) 18 (IBM). For
behavioural experiments, logarithmic transformation (log2)
was carried out on the paw withdrawal thresholds (g) be-
fore statistical analysis as Levene’s test for equality of vari-
ance was significant [69,70]. Analysis of variance (ANOVA)
with repeated measures was used for all time course experi-
ments. To proceed to further post hoc testing at least one
main effect (CFA treatment or toxin) or interaction was re-
quired to be statistically significant (p < 0.05). Subsequent
two-way ANOVA with repeated measures was carried out
to determine if there was an overall effect of CFA or toxiner Sequence
b2F CTAAGAGCCATGTGACTGTC
b2R CAGAACTGTAGGTTTCGG
l10F ATACTCACAGGAACCTAGACAT
l10R CCATCCAACACATCTTGTAATATG
2F GTTCATCAGGCACCAGTC
2R TGACATCGTGGACCAGAA
l9F GATGAAGCCCTTTCATACTGC
l9R GTGGTTGTGAGTTTTGCTCCAATC
r3F AGCCCTCACCTGCATAGTTG
r3R GCCACTAGCTGCAGTACACG
2F GATATCTTCGGTGCGGTCTT
2R GGCCAGATGCTGTAACTCTT
Carr et al. Molecular Pain 2014, 10:39 Page 13 of 14
http://www.molecularpain.com/content/10/1/39across a specific time window. For cell count experiments
and RT-qPCR experiments independent samples t-tests
were used to compare means between two groups. In all
tests a p-value of < 0.05 was deemed significant.Additional files
Additional file 1: Table S1. List of regulated genes identified by
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